Jefferies Initiates BCR At Buy

Jefferies has initiated coverage of C.R. Bard BCR at Buy. According to Jefferies, "BCR continues to execute soundly in the face of persistent and challenging headwinds and we see the top-end of 2011 guidance as achievable. BCR is well-managed, diverse in products, generates solid FCF and industry-leading ROIC, and boasts market leadership across each of its segments, all of which lend support to a premium valuation. As such, we are initiating coverage of BCR shares with a Buy rating and 12-month price target of $115." BCR traded at $99.36 at closing yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsHealth CareHealth Care EquipmentJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!